Louis G. Lange, Director at Esperion Therapeutics, Inc. (ESPR), bought 28,528 shares at $14.00 ($199K) on 2013-07-01, disclosed to the SEC on 2013-07-01.
Open-market purchase of $199k ESPR by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 14,314 | $0 | 0.0% |
| 2 | $14.00 | 3,500 | $49K | 24.6% |
| 3 | $14.00 | 10,714 | $150K | 75.4% |
| Total | $6.98 avg | 28,528 | $199K | 100% |
| Filing → |
| NAMS | BUY | 2024-02-21 | $95K | — | Filing → |
| BOLD | SELL | 2019-12-27 | $656K | — | Filing → |
| BOLD | SELL | 2019-09-25 | $667K | — | Filing → |